Sneeden Campbell

R&D

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.